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Abstract
The fusion of bone marrow (BM) hematopoietic cells with hepatocytes to generate BM derived hepatocytes (BMDH) is a
natural process, which is enhanced in damaged tissues. However, the reprogramming needed to generate BMDH and the
identity of the resultant cells is essentially unknown. In a mouse model of chronic liver damage, here we identify a
modification in the chromatin structure of the hematopoietic nucleus during BMDH formation, accompanied by the loss of
the key hematopoietic transcription factor PU.1/Sfpi1 (SFFV proviral integration 1) and gain of the key hepatic
transcriptional regulator HNF-1A homeobox A (HNF-1A/Hnf1a). Through genome-wide expression analysis of laser captured
BMDH, a differential gene expression pattern was detected and the chromatin changes observed were confirmed at the
level of chromatin regulator genes. Similarly, Tranforming Growth Factor-b1 (TGF-b1) and neurotransmitter (e.g.
Prostaglandin E Receptor 4 [Ptger4]) pathway genes were over-expressed. In summary, in vivo BMDH generation is a
process in which the hematopoietic cell nucleus changes its identity and acquires hepatic features. These BMDHs have their
own cell identity characterized by an expression pattern different from hematopoietic cells or hepatocytes. The role of these
BMDHs in the liver requires further investigation.
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Introduction
For decades, the transformation of a given lineage of a cell into
a completely different one has been suggested as the solution for
numerous tissue specific diseases [1,2,3]. Using different ap-
proaches, this cell lineage switch has been widely explored [4].
Heterokaryon generation by in vitro cell fusion can modify the fate
of differentiated cells [5]. Thus, it has been possible to reprogram
different cell types to skeletal muscle cells by their in vitro fusion
with muscle cells [6,7]. The fusion of human B-lymphocytes with
mouse embryonic stem cells can confer the human cells a
multipotent state [8]. Through somatic cell nuclear transfer, it
has also been possible to change the lineage of a cell to an
embryonic stem cell identity with the capacity to act as a true
embryonic stem cell and generate a complete organism [5,9].
These two different cell reprogramming approaches indicate that
all the elements and pathways required for the conversion of one
cell type into another are present in cells. With this idea in mind,
researchers have identified a subset of genes sufficient to transform
a given cell type into a completely different type. This is the case of
induced pluripotent stem cells (iPSC cells). Thus, the induced
expression of 4 or fewer transcription factors can reprogram
somatic cells to a more primitive state, equivalent to an embryonic
stem cell [10,11,12]. Moreover, through the introduction of tissue
specific transcription factors it has been possible to reprogram cells
directly to other adult cell types [13,14,15].
Cell reprogramming involves modifying the program that gives
rise to the initial specific lineage through gene silencing of the
original transcription profile and acquisition and/or activation of
new pathways from the acquired cell fate [5,16]. This process
occurs in a sequential manner during heterokaryon formation
[6,7,8,17,18] and somatic cell nuclear transfer [19,20,21] or
reprogramming by transcription factors [14,22,23,24]. Indeed,
physiologic cell reprogramming also occurs as a sequential process
involving an intermediate undifferentiated state [23]. Chromatin
remodeling genes play an important role in lineage transforma-
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tion. Several epigenetic mechanisms have also been identified as
contributing to cell lineage switching [25,26,27,28,29]. Changes in
nuclear morphology have also been described [5]. However, it
remains unclear whether epigenetic processes drive cell repro-
gramming or are just the result of cell transformation induced by
lineage specific genes.
Cell fusion is a natural in vivo phenomenon that is highly
regulated and required for development and homeostasis [30] but
also occurs in disease processes such as virus-induced fusion [31]
or tumorigenesis [32]. In some instances, cell fusion occurs
between similarly differentiated cells to acquire completely new
functions, such as the formation of osteoclasts from macrophages
[33]. In vivo cell fusion has also been proposed as a cell
reprogramming mechanism [4,34] responsible, for example, for
the generation of functional non-hematopoietic bone marrow
derived cells, including muscle fibers, neurons or hepatocytes
[35,36,37]. Reports of the generation of bone marrow-derived
hepatocytes (BMDH) have mainly described the fusion of a
myeloid hematopoietic cell lineage with hepatocytes [38,39,40].
The existence of BMDH has been widely reported in different
species [41,42] including humans [43], and their incidence may
vary from rare to representing 20 to 40% of all hepatocytes
[43,44]. The appearance of BMDH is clearly dependent on the
existence of hepatic damage [45]. Previously, we achieved an
increase in BMDH frequency by treatment with granulocyte
colony stimulating factor (G-CSF) in a mouse model of carbon
tetrachloride-induced chronic liver damage [46]. However, despite
extensive research, the processes of generation of BMDH and their
possible roles remain unclear.
We here report that during the generation of BMDH, cell
reprogramming occurs as a series of events in which changes in
both the transcription of specific genes and nuclear structure are
coordinated. In addition, we identified a BMDH-specific gene
expression pattern reflecting observed chromatin organization
changes and pointing to the BMDHs as a new cell identity.
Results
In vivo cell fusion induces nuclear heterochromatin
remodeling
Heterokaryons are produced in vivo through cell fusion. It has been
established that heterokaryon formation induces changes in the
architecture of reprogrammed nucleus [7]. In this study, we
investigated whether these chromatin changes take place during the
formation of BMDH. To do this, a mouse model was used in which
the hematopoietic system had been replaced with exogenous
hematopoietic cells easily traceable. The female recipient mice were
lethally irradiated and transplanted with whole Bone Marrow cells
from male C57BL/6J-bactinEGFPxDBA/2 F1, which express the
eGFP in around 80% of hepatocytes. Animals were subjected to
chronic liver damage three months after bone marrow transplant for
other three months followed by systemic treatment with G-CSF
during three weeks, finally a month late the mice were sacrified. In
prior work, we showed that this treatment significantly enhanced the
appearance of BMDH [46]. BMDH were identified through their
eGFP expression indicating a bone marrow origin, absence of the
hematopoietic marker CD45, and hepatocyte morphology. The
presence of different types of nuclei was observed in the BMDH
which depended on cell size and DAPI staining pattern (Fig. 1A).
Some BMDH had a single clear hepatocyte nucleus, which was large
and had numerous nucleoli, but smaller nuclei could also exist that
were brighter DAPI stained and resembled the nuclei of surrounding
hematopoietic cells. Other BMDH showed nuclei that were of an
intermediate size between a hematopoietic and hepatic nucleus; these
were dimmer DAPI stained. Finally, we also identified BMDH whose
nucleus or nuclei showed clear hepatocyte nucleus morphology.
To further explore the meaning of the different nuclear
morphologies observed, we classified according to their nuclear
morphology and DAPI staining a total of 57 nuclei of the 35
BMDH examined in four different hepatic sections per animal
from a total of eight mice in two independent experiments. We
established DAPI staining profiles for hepatocyte and hemato-
poietic nuclei in non fused cells (Figure 1B). The different BMDH
nuclei were then classified depending on their size and DAPI
staining pattern as: i) Type I, large nucleus of hepatic nuclear
morphology, spherical, with many nucleoli (intensely DAPI
stained); ii) Type II, medium-size nucleus, spherical, evenly
stained, not bright and with few nucleoli; iii) Type III, small
nucleus of hematopoietic nuclear morphology, not spherical,
brightly stained, with few nucleoli (Figure 1B). Additionally, the
DAPI staining pattern of each type of nuclei was maintained
along the nucleus (Figures S4, S5, S6, S7); hematopoietic,
hepatocyte and BMDH nuclei showed a homogeneous DAPI
staining pattern in the different sections as analysed by confocal
microscopy along the Z axis. Among 35 BMDH examined
containing 57 nuclei (see Tables 1, 2 and 3), 18 had only one
nucleus, 15 were binucleated and 2 contained more than two
nuclei. The Type I nuclei were the most represented (around
50% of all the BMDH nuclei), followed by Type II (around 30%)
and finally Type III (around 20%). Among the BMDH with a
single nucleus, all three types defined were represented. Of the 35
BMDH analyzed, 11 BMDH had a Type I nucleus, 10 had a
Type II nucleus and only 1 BMDH had a Type III nucleus.
Additionally, we identified BMDH in which both Type I and
Type II (4 BMDH out of 35) or Type III (9 BMDHs out of 35)
nuclei coexisted, but no single BMDH showed the simultaneous
presence of Type II and III nuclei.
Since the accessibility of DAPI to DNA depends on the extent of
chromatin condensation [47,48], we assessed chromatin conden-
sation using a semi-quantitative approach based on DAPI staining
intensity. The fluorescence densities of BMDH nuclei (FDDAPI)
were calculated in relation to an average fluorescence intensity of
normal hepatocytes (FDDAPINHep) to give a relative fluorescence
value for each BMDH nucleus (Figure S1 and Tables 1, 2 and 3)
as the ratio RF (RF=FDDAPI/FDDAPINHep). These results are
provided in Figure 1C. The RF of the hematopoietic cell nuclei
was significantly higher than 1, indicating a greater extent of
chromatin condensation than in the hepatocyte nuclei. In contrast,
type I and type III BMDH nuclei showed a DAPI relative
fluorescence close to 1. Most importantly, type II BMDH nuclei
returned a RF value that was significantly lower than for the other
types, indicating more chromatin condensation.
Additionally, we identified the origin of the different BMDH
nuclei. Since besides expressing eGFP, cells derived from bone
marrow contained the Y-chromosome (donor mice were male
while recipients were female), we were able to identify the nuclei
derived from the transplanted bone marrow by Y-FISH or Y-
CISH (Figs. 1D, 2A, 2B and S2). Up to 24 nuclei were analyzed by
Y-FISH. Half of them were endogenous and the other half were
exogenous. All the endogenous nuclei have typical Type I
morphology. However, the exogenous nuclei were of any
morphology (2 Type I, 8 Type II and 2 Type III nuclei) (Figure
S2B), indicating that nuclei from bone marrow cells could acquire
the morphology of a hepatocyte nucleus.
Collectively these data suggest that after in vivo cell fusion, the
nuclei of the fused hematopoietic cells undergo transformation to
acquire a similar structure and chromatin condensation to those of
a hepatocyte nucleus.
In Vivo Reprogramming of BMDH
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Fused hematopoietic nuclei switch to a hepatic fate
To determine whether the transformation of fused hematopoi-
etic nuclei was affecting their gene expression, we analyzed the
expression of the key lineage-specific transcription factors of
hematopoietic and hepatic programs, PU.1 and HNF-1A,
respectively, by immunofluorescence. In addition, through simul-
taneous Y-CISH we identified the origin of the different BMDH
nuclei. Most BMDH nuclei lacked PU.1 expression independently
Figure 1. Nuclear chromatin structure modifications produced in the hematopoietic nucleus after in vivo cell fusion during BMDH
formation. A. Presence of nuclei of different morphology in several BMDH as identified by immunofluorescence. Three examples (i, ii and iii) are
shown. Arrowhead, BMDH nucleus with hepatocyte-like nuclear morphology; Arrow, BMDH nucleus with a different morphology to a hepatocyte
nucleus. 20 mm scale bars are shown. B. Classification of the different BMDH nuclei according to their morphology and DAPI DNA-staining. Three
different types of nuclei were defined; hepatocyte-like (Type I), hematopoietic-like (Type III) and non hepatocyte-non hematopoietic-like (Type II).
20 mm scale bars are shown. C. Histogram representing the quantification of DAPI relative fluorescence in the different BMDH (black bars),
hepatocyte and hematopoietic cell nuclei (white bars). The data shown correspond to 57 nuclei of 35 BMDH examined in hepatic sections from
several animals in two independent experiments6 SD. *p,0.05; D. Identifying the origin of BMDH nuclei by Y-FISH and immunofluorescence. Nuclei
positive for the Y-chromosome arise from the exogenous BM. Yellow circle indicates one BM-derived nucleus. 20 mm scale bars are shown.
doi:10.1371/journal.pone.0033945.g001
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Table 1. PU.1 Relative fluorescence (RF) of the three BMDH nucleus types defined.
Type I nucleus Type II nucleus Type III nucleus
BMDH Nucleus A Nucleus B Nucleus C Nucleus D Nucleus E Nucleus F
DAPI RF DAPI RF DAPI RF DAPI RF DAPI RF DAPI RF
1 1.181 0.296 0.558 0.57
2 0.861 0.097 0.789 0.21
3 1.276 0.09 1.113 0.122
4 1.214 0.035
5 0.758 0.143
6 0.975 0.005
7 0.841 0.066
8 0.667 0.37 1.605 0.057
9 0.991 0.12 0.865 0.44
10 0.781 0.038
11 0.67 0.198
12 0.771 0.025 0.869 0.086
13 1.098 0.024 1.174 1
Each row indicates the relative fluorescence (RF) values for DAPI and PU.1 (RF) of all nuclei detected in each BMDH were named alphabetically and classified according
to its morphology (as Type I, II or III).
doi:10.1371/journal.pone.0033945.t001
Table 2. HNF-1A Relative fluorescence (RF) of the three BMDH nucleus types defined.
Type I nucleus Type II nucleus Type III nucleus
BMDH Nucleus A Nucleus B Nucleus C Nucleus D Nucleus E Nucleus F
DAPI RF DAPI RF DAPI RF DAPI RF DAPI RF DAPI RF
14 0.981 0.77 0.861 0.403
15 0.922 0.846
16 0.852 0.888
17 0.796 0.95
18 1.006 1.394
19 1.033 0.402 1.105 1.139
20 0.89 0.521
21 0.951 1.914
22 0.912 1.211
23 1.388 1.541 1.125 0.782
24 0.76 1.723
25 0.633 1.06
26 0.633 1
27 1.012 1.123 0.705 0.877
28 1.01 0.559 0.707 0.966
29 0.935 1.431 0.92 2.255
39 0.663 0.348
31 0.972 0.257 0.887 1.029
32 1.204 1.245 0.752 0.714 0.545 0.245
33 0.75 0.557 0.826 0.771 0.815 0.814 0.62 1.071
34 0.954 0.541 0.836 0.492
35 0.708 0.945
Each row indicates the relative fluorescence (RF) values for DAPI and HNF-1A (RF) of all nuclei detected in each BMDH were named alphabetically and classified
according to its morphology (as Type I, II or III).
doi:10.1371/journal.pone.0033945.t002
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of their cell origin, only 5% of the BMDH nuclei maintained a
PU.1 expression level similar to hematopoietic nuclei (Tables 1, 2
and 3). In contrast, all nuclei of infiltrated hematopoietic cells were
positive for PU.1 (Fig. 2A). In BMDH, only type III nuclei
(hematopoietic nucleus morphology) remained positive for PU.1
expression (Figure S2A). The loss of expression of this master
hematopoietic gene was associated with the global hematopoietic
expression program in the BMDH nuclei of hematopoietic origin,
as revealed by the loss of the pan-hematopoietic marker CD45
(Fig. 1 and array data).
We then went on to address the acquisition of the hepatic
program by detecting the hepatic transcription factor HNF-1A,
essential for a hepatocyte identity. HNF-1A was detected in all
the BMDH nuclei (Fig. 2B and Figure S2B). When we analyzed
the presence of the Y-chromosome in the different BMDH
nuclei, it was found that no BMDH nucleus of hematopoietic
origin was negative for HNF-1A. These observations indicate
that induction of the key hepatic transcription factor HNF-1A
occurs soon after in vivo cell fusion and could activate the
expression of hepatic or BMDH specific genes regulated by
HNF-1A in all BMDH nuclei.
To explore the level of PU.1 and HNF-1A transcription factor
expression in the BMDH nuclei, we calculated and normalized
the presence of both PU.1 and HNF-1A transcription factors by
quantifying their fluorescence intensity. In this semi-quantitative
study, we estimated the fluorescence intensities of the specific
hematopoietic and hepatic nuclear factors, PU.1 (FIPU.1) and
HNF-1A (FIHNF-1A) respectively in BMDH nuclei relative to the
fluorescence intensity of normal hematopoietic cells and
hepatocytes present in the same hepatic tissue section (Figure
S1). Next we calculated the relative fluorescence of PU.1 and
HNF-1A for the different BMDH nuclei (Fig. 2C and 2D,
Tables 1, 2 and 3). The nuclei of hematopoietic cells showed
greatest PU.1 expression and this expression was reduced when
these cells fused with hepatocytes. Interestingly, in type III
nuclei, which are morphologically indistinguishable from hema-
topoietic cell nuclei, PU.1 expression was significantly higher
than in the remaining BMDH or hepatocyte nuclei (Fig. 2C). In
contrast, the presence of HNF-1A was highest in hepatocyte or
type I and type II BMDH nuclei, and was reduced in type III
nuclei (Fig. 2D).
All these observations suggest that when hematopoietic cells and
hepatocytes fuse, the hematopoietic nuclei lose their expression
pattern specific of its lineage and acquire hepatic key regulators.
This is accompanied by a change in nuclear morphology, ending
with the reprogramming of the hematopoietic identity of the
BMDH nucleus to a hepatic fate.
Gene expression profiling of BMDH reveals an
intermediate state between hematopoietic and hepatic
gene expression programs
To further examine the reprogramming process observed in
BMDH, we determined overall gene expression profiles in
microdissected cells using Agilent Whole Mouse Genome Oligo
Microarrays (see Materials and Methods and Figure S3).
Microarray experiments were conducted on hepatic, hematopoi-
etic and BMDH cells obtained from laser microdissected
specimens (see Materials and Methods). Microdissected BMDH
cells were not selected based on the type of nuclei, because RNA
purification and SuperAmplification methodologies are not
compatible with the staining process used to distinguish the
different nuclei. Therefore, the profiling analysis has been
designed to extract common patterns of gene expression in
BMDH cells. Our findings identified 775 Agilent probes
(corresponding to 561 genes) that were deregulated in BMDH
with respect to microdissected hepatocytes and hematopoietic cells
(Fig. 3A) (p-val,0.001) (see Materials and Methods). Under-
expressed genes in BMDH (n = 207) were those involved in
chromosome organization, RNA processing, translation, ubiqui-
tin-dependent catabolism, and mitochondrial biology (Fig. 3B). In
contrast, functional annotation analyses of the overexpressed genes
in BMDH (n = 356) indicated roles in neurotransmission (includ-
ing ligands or receptors), TGFb signaling, and metalloprotease
functions (Fig. 3B). The presence of genes associated with
chromatin remodeling complexes was observed when both under
and overexpressed genes where analyzed for enrichment (Fig. 3B),
in line with the chromatin structural changes observed by DAPI
staining (Fig. 1).
To identify the master regulators of the deregulated genes, we
used the ChEA web tool (see Materials and Methods). ChEA
contains a database of the results of published functional
experiments on transcription factor binding in genomic DNA
through chromatin immunoprecipitation. ChEA allows the
identification through enrichment analysis of factors that act on
a series of listed genes. Therefore, we decided to perform ChEA
analysis using the lists of deregulated genes in BMDH, in order to
extract potential transcription factors that would be regulating
them, and therefore acting in the BMDH reprogramming process.
Transcription factors participating in the regulation of embryonic
development such as Myc, Pou5f1 (Oct4), Klf4, and Sox2, bind
regulatory regions of overexpressed and underexpressed BMDH
genes (Tables 4 and 5). Moreover, polycomb repressor complex
(PRC) genes (Suz12, Eed, Rnf2 or Ring1b, and Ezh2) appeared to
be modulating the transcription of overexpressed genes. Another
transcription factor binding overexpressed BMDH genes is Jarid2
Table 3. Relative fluorescence (RF) of the three BMDH nucleus types defined.
DAPI RF PU.1 RF HNF-1A RF
Hepatocyte nuclei 1.00060.010 (n = 105) 0 (n = 39) 1 (n = 66)
Hematopoietic nuclei 1.15660.022 (n = 105) 1 (n = 39) 0 (n = 66)
Type I nucleus 0.98260.031 (n = 29) 0.12960.035 (n = 11) 0.99460.127 (n = 18)
Type II nucleus 0.75160.028 (n = 17) 0.05060.019 (n = 3) 0.94060.106 (n = 14)
Type III nucleus 0.91660.086 (n = 11) 0.40360.143 (n = 6) 0.63860.113 (n = 5)
Each row indicates the average of relative fluorescence (RF) values for DAPI and transcription factors (PU.1 RF and HNF-1a RF) in the nuclei of control cells
(hematopoietic cells and hepatocytes).
doi:10.1371/journal.pone.0033945.t003
In Vivo Reprogramming of BMDH
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(Jumonji). This gene has been identified as essential for liver
development and hepatocyte maturation [49].
In injured mouse liver, PU.1, which is expressed in most
hematopoietic cells and whose expression is activated during
myeloid and B-lymphoid cell development, showed reduced or no
staining in BMDH cells (Fig. 2). Transcription factor enrichment
analysis confirmed this pattern, since PU.1 targets were also down
regulated in these cells (Table 5). We could not test whether HNF-
1A was overexpressed in BMDH, as no ChIP experiment was
included in the ChEA database. However, we did detect
significant enrichment in genes regulated by HNF-4a (Table 4),
which in turn regulates HNF-1A and may play a role in the
differentiation of BM derived cells towards a hepatic fate.
Overall, ChEA enrichment indicated that BMDH are repro-
grammed cells whose expression patterns are consistent with the
gain of liver expression patterns at the expense of a loss in the
typical expression profile of a hematopoietic lineage.
BMDH acquire a specific gene expression fingerprint
including deregulation of the TFGb pathway and
expression of neurotransmitters
Interestingly, a considerable number of overexpressed genes
observed in BMDH included those of the TGFb pathway and
neurotransmitters (Fig. 3B). This upregulated expression of Tgfb1
and the neuroreceptor Ptger4 was confirmed by immunofluores-
cence labeling (Fig. 4). The presence of Tgfb1 in BMDH (Fig. 4B)
confirms the deregulation of TGFb signaling during the
reprogramming process. Ptger4 was also identified mainly in
BMDH (Figure 4C), although a small proportion of other cells
were also positive for this neuroreceptor (data not shown).
Functional annotation analyses revealed that several genes of
the TGFb signaling pathway, including Rps6kb1 (p70S6K), Nog
(noggin), Inhbb (Inhibin b-B), Gdf5, and Smad9, are deregulated
in BMDH cells. Additionally, TGFb1 was detected in BMDH by
immunofluorescence (Fig. 4B). Also, ChEA revealed that targets of
Smad1, 2, 3 and 4 are downregulated, and that targets of Smad 1
and Pax3-Fkhr (involved in Smad2/3 signaling) are overexpressed
(Tables 4 and 5). These results suggest that TGFb pathway is
deregulated during the reprogramming process. If this deregula-
tion is a cause or effect in the BMDH generation is unknown.
Neurotransmitter genes found to be modulated in BMDH were
those with a role in synaptic functions (Als2, Chrna5, Cplx2,
Cplx4, Des, Dmxl2, Gabbr1, Gabra6, Gabrb1, Gabrg1, Glra2,
Homer1, Itsn1, Myo7a, Otof, Phactr1, Rims1, Rps6kb1, Snph,
Sv2b, Syn3, and Syt5) including neurotransmitters and neuror-
eceptors such as G-protein coupled receptors (GPCRs) (Table S1
and S2). Master regulators of neurogenesis are bound to the
regulatory regions of both overexpressed and underexpressed
genes, such as Rest or Rcor1 (Tables 4 and 5). Both these genes
are transcriptional repressors that repress neuronal genes in non-
neuronal tissues. As most synapse genes regulated by Rest or
Rcor1 appeared overexpressed in BMDH, our data suggest that
their repressor function was inhibited. The functional consequenc-
es of a neuronal program in BMDH cells remain to be determined.
Discussion
In vivo fusion has been described as the main mechanism giving
rise to non-hematopoietic bone marrow derived cells [35,36,37].
This process is promoted when there is tissue damage and the
appearance of BMDH has even been associated with the
amelioration of hepatic dysfunction [41]. Cell fusion is also
thought to be a natural process that leads to the generation of
tissues such as muscle fibers, and of specialized cells such as
osteoclasts or giant cells from macrophages [30]. The cell
reprogramming that takes place after cell fusion has been
extensively explored in vitro [6,7,8] and despite BMDH having
been widely reported [35,36,37,40,41,45,46], little is known about
how similar processes occur in vivo. Moreover, a role for BMDH in
hepatic repair has not been clearly established. In this study, we
propose that the fusion of a hematopoietic cell with a hepatocyte
triggers the reprogramming of the hematopoietic cell nucleus until
Figure 2. Gradual loss of master hematopoietic transcription
factor PU.1 and gain of master hepatic transcription factor
HNF-1A in BMDH nuclei. A. Absence of hematopoietic transcription
factor PU.1 in two nuclei of a BMDH derived from BM cells (arrows) as
identified by immunofluorescence and Y-CISH (black dots). 20 mm scale
bars are shown. B. Presence of hepatic transcription factor HNF-1A in
two nuclei of a BMDH derived from an endogenous hepatocyte
(arrowhead) and a BM cell (arrow). 20 mm scale bars are shown. C.
Quantification of PU.1 relative fluorescence in BMDH, hepatocyte and
hematopoietic cell nuclei. Data shown correspond to 20 nuclei of 13
BMDH examined in hepatic sections from several animals in two
independent experiments. Data expressed as means 6 SD. *p,0.05. D.
Quantification of HNF-1A relative fluorescence in BMDH, hepatocyte
and hematopoietic cell nuclei. Data shown correspond to 37 nuclei of
22 BMDH examined in hepatic sections from several animals in two
independent experiments. Data expressed as means 6 SD. *p,0.05.
doi:10.1371/journal.pone.0033945.g002
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it resembles a hepatocyte nucleus, both in its morphology and
functionality. However, through a detailed gene expression
analysis of these BMDH, we observed a distinct self-identity of
these liver cells, as the overexpression of several components of the
TGFb pathway and of neurotransmission proteins involved in
intercellular signaling.
In order to study BMDH generation, we have relied on eGFP
expression in hepatocytes for identification of BMDH. We
assumed a possible underestimation of 20% in the frequency of
occurrence of BMDH, due to variegation in the expression of the
marker transgen, where around 80% of hepatocytes from the
transgenic mice used as BM donors, express eGFP. However,
Figure 3. BMDH show a different gene expression profile to hematopoietic and hepatic cells. A. Heatmap of BMDH deregulated genes.
Genes were selected based on Pearson’s correlation on a template pattern of deregulated gene expression in BMDH cells, with respect to
microdissected hepatocytes (Hep) and hematopoietic cells (Hem), and also to control mouse liver (L), macrophage (M) or B cells (B) (p-val,0.001) (see
Materials and Methods). B. Functional annotation analysis of deregulated genes using the DAVID web tool (see Materials and Methods).
doi:10.1371/journal.pone.0033945.g003
In Vivo Reprogramming of BMDH
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BMDH generation mechanism is independent of the expression of
eGFP, as in transgenic mice themselves the expression of this
marker gene does not affect any cell type. In our model, we have
analysed a snapshot of this process where we have been able to
identify differences in BMDHs, which might mean different stages
in the in vivo cell fusion reprogramming process.Once fused with a
hepatocyte, the hematopoietic cell nucleus starts its transforma-
tion. As other authors have described previously in vitro [5,7], we
have observed a similar process might take place in our in vivo
Table 4. Transcription factor genes upregulated in BMDH.
Overexpressed
TF-Expt ID1 Genes2 p-val3
EED-16625203 21 6.5E-05
EP300-20729851 49 8.2E-09
EZH2-18974828 40 1.4E-10
HNF4A-19822575 75 0.009
JARID2-20064375 34 4.8E-09
JARID2-20075857 37 2.4E-09
KLF4-18358816 29 0.002
KLF4-19030024 32 2.4E-05
MYC-18358816 42 0.05
MYC-19030024 49 0.02
MYC-19079543 22 0.02
MYC-19915707 50 6.9E-05
MYC-20876797 21 0.03
NANOG-16518401 48 0.007
NANOG-18347094 29 0.009
NANOG-18358816 21 0.008
NANOG-18692474 47 7.6E-04
NANOG-21062744 15 0.02
PAX3-FKHR-20663909 21 0.002
POU5F1-16518401 34 7.4E-06
POU5F1-18347094 30 0.02
POU5F1-18358816 13 0.03
POU5F1-18692474 73 3.7E-07
RCOR1-19997604 47 2.0E-06
REST-18959480 54 1.4E-06
RNF2-16625203 27 5.7E-05
RNF2-18974828 40 1.4E-10
SMAD1-18555785 15 9.4E-04
SOX2-18358816 14 0.02
SOX2-18555785 10 0.02
SOX2-18692474 53 1.4E-04
SOX2-19030024 20 3.0E-04
SOX2-21211035 60 3.0E-06
SUZ12-16625203 36 1.0E-08
SUZ12-18555785 31 5.5E-08
SUZ12-18692474 62 4.8E-17
SUZ12-18974828 58 1.6E-14
SUZ12-20075857 105 1.2E-19
ChEA software was used to identify transcription factors that could regulate the
expression of BMDH genes with respect to microdissected cells (hematopoietic
and hepatocytes) and mouse macrophages, B cells and liver tissue.
1TF: transcription factor symbol; Expt ID: PubMed ID for the publication.
2Number of the BMDH genes regulated by the TF.
3Significance of the gene overlapping.
doi:10.1371/journal.pone.0033945.t004
Table 5. Transcription factor genes downregulated in BMDH.
Underexpressed
TF-Expt ID1 Genes2 p-val3
EP300-20729851 28 1.4E-04
EP300-21415370 13 0.01
HNF4A-19761587 26 1.7E-08
HNF4A-19822575 97 6.7E-20
KLF4-18358816 27 1.1E-05
KLF4-18555785 52 8.0E-15
KLF4-19030024 18 0.007
MYC-18358816 59 5.9E-13
MYC-18555785 29 8.7E-10
MYC-18940864 9 0.05
MYC-19030024 81 3.0E-23
MYC-19079543 28 2.0E-07
MYC-19915707 29 0.01
MYC-20876797 16 0.02
NANOG-16518401 34 0.008
NANOG-18347094 20 0.02
NANOG-18358816 17 0.002
NANOG-18555785 10 0.003
NANOG-18692474 50 3.4E-10
NANOG-21062744 12 0.007
POU5F1-18347094 35 1.7E-07
POU5F1-18358816 11 0.009
POU5F1-18555785 16 6.9E-07
POU5F1-18692474 66 1.7E-12
POU5F1-18700969 9 0.01
RCOR1-19997604 25 0.008
REST-18959480 29 0.008
REST-19997604 27 4.0E-04
SFPI1-20887958 44 1.1E-10
SMAD1-18555785 10 0.006
SMAD2-18955504 26 2.4E-04
SMAD3-18955504 26 2.4E-04
SMAD4-19686287 6 0.04
SOX2-18358816 10 0.03
SOX2-18555785 8 0.01
SOX2-18692474 55 2.2E-11
SOX2-19030024 17 4.1E-05
SOX2-20726797 30 7.7E-04
SOX2-21211035 43 8.8E-06
ChEA software was used to identify transcription factors that could regulate the
expression of BMDH genes with respect to microdissected cells (hematopoietic
and hepatocytes) and mouse macrophages, B cells and liver tissue.
1TF: transcription factor symbol; Expt ID: PubMed ID for the publication.
2Number of the BMDH genes regulated by the TF.
3Significance of the gene overlapping.
doi:10.1371/journal.pone.0033945.t005
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model. First, by differential DAPI staining, we noticed a change in
nuclear structure. In BMDH, the non-hepatic nucleus is enlarged
while it becomes more inaccessible to the DNA intercalating agent
DAPI (Fig. 1). The gradual reduction in fluorescence emitted by
DAPI defines the transition from an early stage of the so-called
type III nucleus, hematopoietic-like in shape, to an intermediate
type II nucleus. We have been demonstrated the bone marrow
origin of all the Type III and Type II nuclei, and also of some of
Type I using Y-FISH, indicating their hematopoietic origin. This
transition is also characterized by a gradual increase in hepatic
transcription factor HNF-1A and the sudden non-expression of the
hematopoietic transcription factor PU.1 in the changing nucleus.
This nuclear transformation ends when the non-hepatic nucleus
becomes a hepatocyte-like nucleus (type I nucleus), which is
morphologically indistinguishable from an endogenous hepatocyte
nucleus and only expresses hepatic transcription factor HNF-1A.
Similar changes in nuclear structure, nuclear enlargement and
chromatin modification, have been described during the genera-
tion of heterokaryons in vitro [5,7]. These changes have been
related to a process of chromatin remodeling [7,17,18,25]
involving mechanisms such as demethylation of tissue-specific
gene promoters [8,18] or histone deacetylation [7,17], among
others. Here we were able to track chromatin remodeling through
the detection of nuclear reshaping and modifications deduced
from the microarray analyses.
Our array data reveal the important role of chromatin
modification in in vivo BMDH generation. For example, NuSAP
plays a crucial role in spindle microtubule organization; it is
expressed during the transition from G2 to mitosis and localized in
the nucleoli during interphase [50]. Thus, the observed overex-
pression of NuSAP in BMDH could contribute to the formation of
a hepatocyte-like nucleus with numerous nucleoli. In contrast,
BMDHs show reduced expression of the genes SATB2, BCOR
and Ep400. SATB2 regulates the expression of several genes (e.g.
Nanog [51]) and the chromatin structure of multigene clusters (e.g.
Hox gene clusters [52]). Its reduction in BMDH could cause gene
silencing during cell reprogramming. BCOR binds to BCL6 to
exert a repressive role in B cells and polycomb family members of
the BCOR-BCL6 complex are also capable of gene silencing [53].
Ep400 forms part of a large chromatin-remodeling complex and is
essential for the expression of Hox genes in hematopoiesis and for
cell cycle progression [54,55]. On the other hand, according to our
ChEA analyses, polycomb repressor complex (PRC) genes (Suz12,
Eed, Rnf2 or Ring1b, and Ezh2) appear to modulate the
transcription of overexpressed genes. Since PRC genes are protein
repressors, targeted proteins may detach from the promoters
during BMDH reprogramming, allowing the induction of target
genes. The alteration of these genes and others involved in nuclear
structure remodeling could play an important role in the cell
reprogramming of BMDH.
Here we clearly show a change in the expression of key tissue-
specific genes in the nuclei of the fused hematopoietic cells. PU.1
disappears from the type III nuclei to the transition type II nuclei,
but HNF-1A appears at an early stage in the new BMDH nuclei
(Fig. 2). The reduction in levels of PU.1 indicates early silencing of
the hematopoietic expression program of these nuclei (Tables S1
and S2). During the formation of heterokaryons between mouse
muscle cells and human keratinocytes, cell reprogramming was
Figure 4. Tgfb1 and Ptger4 are overexpressed in BMDH. A. Hepatic section sequentially stained, as described in Materials and Methods, for
eGFP detection and with the secondary antibody donkey anti-rabbit-TexasRed. B. Tgfb1 expression in BMDH. C. Ptger4 presence in BMDH. 20 mm
scale bars are shown.
doi:10.1371/journal.pone.0033945.g004
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recently described as a fast process [6]. This would explain why
the type III nuclei present in a fused cell are HNF-1A positive, but
have not yet fully silenced PU.1 (Fig. 2C and 2D).
It may be argued that the presence of HNF-1A in a type III
nucleus is the outcome of activation of a hepatic program in this
nucleus or may be due to migration of this transcription factor to
the exogenous nucleus. Regardless of the source of HNF-1A,
BMDH nuclei arising from hematopoietic cells became hepatic-
like nuclei as demonstrated by the presence of the Y-chromosome
(Fig. 2 and Figure S2). It has been broadly demonstrated that
specific transcription factors can promote the generation of cells of
a completely different fate [10,12,13,14,28,34,56,57]. Thus, the
hepatic transcription factors present in our heterokaryons could
induce the reprogramming of the hematopoietic nucleus to a
hepatic fate.
The cell reprogramming process may even be bidirectional [6].
In our model, the hematopoietic cell might reprogram the
hepatocyte nucleus in the fused cells. We may assume that the
balance here is shifted towards acquiring a hepatic phenotype for
two main reasons: i) the direction of reprogramming by fusion in
vitro depends on the ratio between the two cell types [6], and ii)
extracellular signals in the liver are able to transdifferentiate
hematopoietic cells to hepatocytes [58].
Using different techniques we found that the key hematopoietic
transcription factor PU.1 was silenced in BMDH. Our ChEA
analysis also revealed that some PU.1 gene targets are also
deregulated in BMDH. Some of these PU.1 targets are involved in
chromatin remodeling (Aebp2, Chd9, Rbbp7, or Tnks2), suggest-
ing that PU.1 regulates reprogramming processes in BMDH cells.
The lack of PU.1 expression could facilitate cell reprogramming
via chromatin remodeling changes due to the down regulation of
specific chromatin remodeling genes. In addition, the key hepatic
transcription factors HNF-1A and HNF-4a were identified here in
BMDH by immunofluorescence and microarrays analysis, respec-
tively. Ectopic HNF-4a expression seems to be needed to direct in
vitro hepatic differentiation from BM cells [57]. Whether HNF-1A
is positively activated by HNF-4a in BMDH remains to be
determined, but we suggest that a liver specific expression program
associated with HNF factors comes into play.
In Caenorhabditis elegans, direct in vivo reprogramming generates
undifferentiated intermediate states that precede redifferentiation
into the new cell type [23]. Our array data indicate that the
transcription pathways regulated by the pluripotent transcription
factors Oct-4, Klf-4, Sox2, and also c-Myc, are clearly modulated
in BMDH, suggesting the existence of an intermediate and
undifferentiated state (i.e. type II nuclei).
According to our array data, the final conversion of BMDH into
a hepatocyte is not complete. Thus, in our case the fused nucleus
may preserve part of its hematopoietic identity and continue to
express certain hematopoietic genes or hematopoietic epigenetic
marks (Tables S1 and S2). As is likely for genes involved in
chromatin organization, these genes specific to BMDH could
participate in the process of cell reprogramming, or could
represent the acquisition of a new role of newly generated
BMDH. In effect, the genes showing clear differential expression
in BMDH include those coding for various components of the
TGFb pathway, several neuroreceptors and cytokines (Fig. 3 and
Tables S1 and S2). Among these, we show here by immunoflu-
orescence the differential protein expression of TGFb and
PTGER4 in BMDH. The TGFb pathway has been widely
incriminated in liver repair processes [59]. BMDH are mainly
generated in the context of hepatic damage [46] such that it is
likely that these BMDH participate in the liver repair mechanism.
Moreover, the genes specific to BMDH encoding neuroreceptors
(Tar, Agtrl1, Npffr, Oxtr, Par, Ptger4, Trhr, Crhr, Grm, Gabra6,
Gabrb1, Gabbr1 and Lepr) or cytokines (Ccl28, Il12b, Csf2,
Ifna13, Inbb and Gdf5) take part in different signaling processes,
pointing to a possible signaling role of BMDH in hepatic repair.
Materials and Methods
Animal procedures and tissue collection
All experimental procedures were approved by the ethics
committee of the CIEMAT accorded to Spanish and European
directives (Approval ID# 28079-21A of the Ministerio de Medio
Ambiente, Medio Rural y Marino). C57BL/6JxDBA/2 F1 female
mice were subjected to lethal irradiation and intravenously
injected with 1?107 whole bone marrow cells harvested from
C57BL/6J-bactinEGFP (kindly provided by Dr. M. Okabe,
Osaka, Japan)6DBA/2 F1 male mice. Three months post
transplantation, the mice were intraperitoneally injected with
1?1022 mol/Kg of body weight of CCl4 (Fluka, Buchs, Switzer-
land) in olive oil on a weekly basis for three months. To induce
BMDH formation, prior to sacrifice the hepatic injured animals
were hematologically mobilized through a 3-week course of
subcutaneous injections of 50 mg of pegylated granulocyte colony
stimulating factor (Neulasta, Amgen, Breda, Netherlands) in PBS/
0.1% BSA.
For tissue collection, animals were transcardially perfused with
10 ml cold PBS/20 mM EDTA, followed by 25 ml cold 4%
paraformaldehyde (PFA, Merck, Darmstadt, Germany). Liver
lobes were fixed in 4% formalin and paraffin-embedded or
incubated in 30% sucrose/PBS at 4uC overnight and kept in OCT
(Sakura Finetek, Zoeterwoude, Netherlands) at 280uC until
analysis.
Immunohistological analysis
All immunofluorescence and in situ hybridization procedures
were performed on 5-mm sections of paraffin-embedded tissue. For
the co-localization of enhanced GFP (eGFP) and CD45, tissue
sections were digested with Proteinase K (Dako, Carpinteria, CA),
blocked and incubated with rabbit anti-eGFP (20 mg/mL,
Molecular Probes, Eugen, OR) or goat anti-eGFP (Abcam,
Cambridge, UK) and biotinylated anti-CD45 (1.25 mg/mL, 30-
F11 clone, BD Bioscience Pharmingen, San Jose, CA) antibodies.
After washing, the samples were incubated with donkey anti-rabbit
AlexaFluorH488 or Donkey anti-goat-FITC (Jackson ImmunoR-
eseach, West Grove, PA) and streptavidin AlexaFluorH594
antibodies (2 mg/mL and 4 mg/mL respectively, Molecular
Probes). Finally, nuclei were stained with 4,6-diamidino-2-
phenylindole (DAPI, Boehringer, Ingelheim, Germany) dissolved
in Mowiol (Sigma-Aldrich, Steinheim, Germany) as mounting
medium. For nuclear staining, a multistep protocol was per-
formed. In brief, tissue sections were treated with boiling citrate
buffer (10 mM sodium citrate/4.4 mM chloridric acid, pH 6),
blocked, incubated with rabbit anti-PU.1 (8 mg/mL, T-21 clone,
Santa Cruz Biotechnology, Santa Cruz, CA) rabbit anti-HNF-1A
(8 mg/mL, H-205 clone, Santa Cruz Biotechnology), rabbit anti-
PTGER4 (40 mg/mL, MBL, MA) or rabbit anti-TGFb1 (Santa
Cruz Biotechnology) antibodies overnight at 4uC. After washing
and adding donkey anti-rabbitTexasRed (7.5 mg/mL, Jackson
Immunoresearch Laboratories, Cambridgeshire, UK), the samples
were washed, blocked, incubated sequentially with rabbit anti-
eGFP and donkey anti-rabbit AlexaFluorH488, and mounted. The
tissue sections were analysed with an Axioplan 2 imaging
fluorescent microscope (Zeiss, Jena, Germany) or with Bio-Rad
Radiance 2100 confocal system (Zeiss) when Z-stack analyses were
performed.
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Fluorescence quantification
Four tissue sections from different hepatic lobes per animal of
eight animals of two independent experiments were used for the
fluorescence quantification of DAPI, PU.1 and HNF-1. To
quantify the density of fluorescence due to DAPI staining of
nuclei, we used Image Tool 3.00 software (University of Texas,
San Antonio, TX). The fluorescence density of different nuclei was
calculated in the blue channel; DAPI relative fluorescence (Figure
S1) for each nucleus was defined as the relationship between the
DAPI fluorescence density of a nucleus with respect to the
arithmetic mean of the DAPI fluorescence density values obtained
for hepatocyte nuclei used as controls in each image. To quantify
relative fluorescence for PU.1, we determined the PU.1 fluores-
cence density value and PU.1 fluorescence density values for the
nuclei of three different hematopoietic cells and hepatocytes;
thereby avoiding differences in fluorescence between different
images. DAPI relative fluorescence was calculated for 57 BMDH,
105 hepatocyte and 105 hematopoietic nuclei. We calculated PU.1
relative fluorescence for each BMDH nucleus and control nuclei
according to the equation in Figure S1, in which PU.1 nuclear
fluorescence is referred to the PU.1 fluorescence of hematopoietic
cell nuclei after subtracting the autofluorescence of hepatocyte
nuclei. Thus, PU.1 relative fluorescence of the hematopoietic
nuclei will be 1 and that of the hepatocyte nuclei will be 0. PU.1
relative fluorescence was calculated for 20 BMDH, 39 hepatocyte
and 39 hematopoietic nuclei. Similarly, we calculated HNF-1A
relative fluorescence using the equation in Figure S1, in which
HNF-1A nuclear fluorescence is referred to the HNF-1A
fluorescence of hepatocyte nuclei once the autofluorescence of
the hematopoietic cell nuclei in the red channel has been
subtracted. This time the HNF-1A relative fluorescence of the
hepatocyte nuclei will be 1 and that of hematopoietic cell nuclei
will be 0. HNF-1A relative fluorescence was calculated for 37
BMDH, 66 hepatocyte and 66 hematopoietic nuclei. Relative
fluorescence values were compared using the nonparametric
Wilcoxon Mann-Whitney test and Kruskal Wallis test implement-
ed in the Statgraphics software package (Manugistic Inc, Rock-
ville, MD). Data are expressed as the mean 6 standard error. The
level of statistical significance was set at p,0.05.
Y-chromosome in situ hybridization
To simultaneously detect the presence of the Y chromosome
and eGFP expression, Y-chromosome fluorescence in situ hybrid-
ization (Y-FISH) was conducted using the Star FISH Kit (Cambio,
Cambridge, UK) according to the manufacturer’s instructions. On
the same sections, eGFP expression was identified by immunoflu-
orescence as described above. The presence of the Y chromosome
in the BMDH previously stained for different nuclear factors was
detected by Y-chromosome chromogenic in situ hybridization (Y-
CISH) and developed using the ABC kit (Vector Laboratories,
Burlingame, CA).
Laser cell capture and mRNA superamplification
For laser capture of individual cells, 12–15 mm frozen sections
were analyzed under an Olympus IX81 motorized inverted
microscope equipped with a laser catapulting microdissection
device (Zeiss, Jena, Germany) (Figure S3). BMDH were identified
according to their hepatocyte morphology, eGFP expression and
lack of autofluorescence; hepatocytes according to their morphol-
ogy and lack of eGFP expression; and hematopoietic cells
according to their smaller size and eGFP expression. Tissue
surrounding the cells of interest was destroyed by laser-burning.
These isolated cells were catapulted to Eppendorf caps and then
lysed in SuperAmp lysis buffer and stored at 280uC according to
the instructions of the SuperAmp Preparation kit (Miltenyi Biotec,
Bergisch Gladbach, Germany). SuperAmplification was per-
formed according to Miltenyi Biotec’s undisclosed protocol. The
integrity of cDNA was checked using the Agilent 2100 Bioanalyzer
platform (Agilent Technologies, Palo Alto, CA). The average
length of the library PCR products was 200–1000 bp.
Gene expression microarray analysis
Superamplified cDNA was hybridized according to the Agilent
60-mer oligo microarray processing protocol employing the Agilent
Gene Expression Hybridization kit (Agilent Technologies) utilizing
1.25 mg Cy3-labeled fragmented cRNA on Agilent whole mouse
genome oligo microarrays. As controls we used microarray data
obtained using the same Agilent chip for mouse macrophages, B
cells and liver tissue [60]. Raw data were downloaded from the
GEO database (datasets GSE21512 and GSE14921). The Agilent
feature extraction software (FES) was used to read out and process
the microarray image files. Raw data were normalized by quantile
normalization [61]. Two BMDH samples were discarded because
of defective normalization. The final dataset contained the following
biological replicates: 56 BMDH, 36 hepatocytes, and 36
hematopoietic cells. Genes deregulated in BMDH cells were
extracted by Pavlidis template matching [62]. Briefly, Pearson’s
correlation coefficient is computed between the intensities measured
for each gene and the values of an independent variable. P-values to
test for the null hypothesis that the correlation is zero are calculated.
The independent value acts as a template where certain expression
patterns could be analyzed. The independent value (template) was
selected to search for genes overexpressed (or underexpressed) in
BMDH cells with respect to microdissected cells (hematopoietic and
hepatocytes) and mouse macrophages, B cells and liver tissue. The
threshold significance values used were: p-val,0.001 and Pearson
coefficient R.0.65 (overexpressed in BMDH) or R,20.65
(underexpressed in BMDH). Enrichment analyses of Gene
Ontology terms and KEGG pathways were performed using the
web utility DAVID (http://david.abcc.ncifcrf.gov) [63]. ChIP
Enrichment Analysis (ChEA) software (http://amp.pharm.mssm.
edu/lib/chea.jsp) was used to search for transcription factors that
could be controlling the expression of the genes deregulated in
BMDH cells [64]. Briefly, a database of ChIP-chip, ChIP-seq,
ChIP-PET and DamID experiments, whereby interactions of
specific transcription factors with their DNA binding sites are
determined, was generated (ChIP-X database) [64]. The database
contains 189,933 interactions, manually extracted from 87
publications, describing the binding of 92 transcription factors to
31,932 target genes. We used this database to analyze BMDH
mRNA expression data. ChEA software computes over-represen-
tation of transcription factor targets from the ChIP-X database. The
output of the analysis is the factors that could be acting in the
BMDH cells, and the number and list of BMDH deregulated genes
regulated by each factor. Same transcription factor could appear
more than once (such as MYC, NANOG, etc), as different
experiments have been reported for the same factor (identified by
the PMID of each report). Raw and processed microarray data
generated in this study accomplish MIAME guidelines, and has
been deposited in the GEO database under the accession number
GSE29878.
Supporting Information
Figure S1 Mathematical equations used to calculate
relative fluorescence (RF) values for DAPI, PU.1 and
HNF-1A (see Experimental Procedures).
(TIF)
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Figure S2 Identification of PU.1 and HNF-1A in BMDH
nuclei. Additional examples of identification of PU.1 and HNF-
1A in BMDH by immunofluorescence and Y-CISH. A. PU.1
analysis in the nuclei of BMDH originating from endogenous
hepatocytes (arrowhead) or BM cells (arrows). B. Presence of
HNF-1A in a multinucleated BMDH originating from endogenous
hepatocytes (arrowhead) or BM cells (arrows). 20 mm scale bars are
shown.
(TIF)
Figure S3 Laser capture procedure used to obtain
isolated BMDH for further molecular analyses. BMDH
were selected according to a clear hepatocyte like morphology (A)
and their eGFP expression (B). C. To ensure that only the selected
cell is captured, the tissue surrounding the cell of interest is burned
out with the laser beam. D. The selected cell is catapulted to an
Eppendorf tube cap for further RNA extraction.
(TIF)
Figure S4 Z-stack confocal analysis. DAPI staining pattern
of different nuclei (A) and identification of eGFP (green), CD45
(red) and DAPI (blue) staining (B) along Z-axis is represented as a
serial 0.25 mm frames separate each 1 mm. BMDH (dotted line),
hematopoietic (arrowhead) and hepatocyte (arrow) nuclei are
shown.
(TIF)
Figure S5 Z-stack confocal analysis of a BMDH with a
Type I nucleus. DAPI staining pattern of different nuclei (A) and
identification of eGFP (green), CD45 (red) and DAPI (blue)
staining (B) along Z-axis is represented as a serial 0.25 mm frames
separate each 1 mm. BMDH (dotted line) and hepatocyte (Type I,
asterisk) nuclei are shown.
(TIF)
Figure S6 Z-stack confocal analysis of a BMDH with a
Type I and a Type II nuclei. DAPI staining pattern of different
nuclei (A) and identification of eGFP (green), CD45 (red) and
DAPI (blue) staining (B) along Z-axis is represented as a serial
0.25 mm frames separate each 1 mm. BMDH (dotted line), Type II
(arrowhead) and hepatocyte (Type I, asterisk) nuclei are shown.
(TIF)
Figure S7 Z-stack confocal analysis of a BMDH with a
Type I and a Type III nuclei. DAPI staining pattern of
different nuclei (A) and identification of eGFP (green), CD45 (red)
and DAPI (blue) staining (B) along Z-axis is represented as a serial
0.25 mm frames separate each 1 mm. BMDH (dotted line), Type
III nucleus (arrowhead) and hepatocyte nucleus (Type I, asterisk)
are shown.
(TIF)
Table S1 Overexpressed genes in BMDH.
(XLS)
Table S2 Underexpressed genes in BMDH.
(XLS)
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